Franck Lescure

Supplies gases, technologies and services for the industry & health businesses

Auriga Partners invests in small and mid sized companies located in France and Europe. The firm targets companies operating in the fields of IT and life science sectors. It provides financing for seed and early stage capital requirements with an investment size ranging between EUR 1 - 5 million and also take minority stakes.

Operates as a clinical-stage biopharmaceutical company that manufacture immuno-oncology and inflammation products

Elaia is an active, long-term manager which invests in software technology companies, primarily in France and on a case by case basis in other European countries. The firm typically invests €1-€2 million, alone or through syndicated rounds, allocating additional financing to the future financing needs of the investee company. Elaia's investment strategy aims to maximize diversification within software-related technologies. They seek to create a balanced portfolio allocation based on four diversification criteria: development stage, geographical location, economic model and market segment. The firm invests in companies in all development stages, with an emphasis on first rounds of venture capital and the ability to participate in special situations. This multi-stage approach generates a broad range of risk/reward profiles and different exit perspectives. They diversify by sector and economic model to address the widest range of opportunities within the software-related field. By diversifying geographically, they aim to allocate approximately 20% of their portfolio to European opportunities outside France, to provide better access to an international network and enlarge their understanding of the markets. Elaia participates as lead investor or as a follower in a syndicate, typically seeking a board position to accompany the management team through the key stages of the investee company's development, aiming to add value to the company. The firm seeks to invest in innovative, well-managed, high-growth companies in large, appealing markets, which meet customer's needs, ideally have an existing customer base, a realistic and sustainable business model and reasonable company valuation.

Engages in the development and market of software publishing solutions and provision of services in the field of medical imaging in oncology

Functions as a College/University

Develops medicinal products for orphan oncology and rare diseases

Operates an organisation for growth of health industry

Provides hotel online reservation solutions